Join
Live feed
·
PRReleasevia Quantisnow
Aadi Bioscience Inc. logo

Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

ByQuantisnow·Wall Street's wire, on your screen.
AADI· Aadi Bioscience Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AADI (Aadi Bioscience Inc.) and more on Quantisnow.